Dear EURETINA Members, A very warm welcome to the June 27th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »June 27th, 2024 “EURETINA-Brief”© Issue No. 294
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the completion in the first cohort for a Phase… Read More »Opus Genetics Inc., has announced completion of dowsing in first cohort Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.
A new real-world study, led by Massachusetts General Hospital, Harvard Medical School, Boston, US, have reported a major adverse event on hydroxychloroquine retinopathy, with an… Read More »Hydroxychloroquine dose and duration of use are associated with the risk of hydroxychloroquine retinopathy in a US study.
Researchers based at the MRC Human Genetics Unit, at the University of Edinburgh, and the Western General Hospital (Edinburgh), have reported a new study indicating… Read More »X-linked retinitis pigmentosa (XLRP) due to RPGR variants report new data on actin dynamics.
Dear EURETINA Members, A very warm welcome to the June 10th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »June 10th, 2024 “EURETINA-Brief”© Issue No. 293
A consortium of researchers across Australia, New Zealand, USA, Italy, Portugal, Singapore, Netherlands, Taiwan and Canada, have reported a new study evaluating clinical, electrophysiological and… Read More »Variants in peripherin 2 (PRPH2 gene) shows genetic, functional and clinical observations on 241 IRD patients.
A large real-world prospective study on the long-term effectiveness and safety of faricimab and “Port Delivery System with ranibizumab” (PDS), for nAMD or DME, is… Read More »Real-world data on treatment of AMD/DME patients with faricimab and port delivery system with ranibizumab will run to 2027 (“VOYAGER” ).
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced the completion of dosing in their second cohort of its Phase 1/2… Read More »Ocugen Inc completes dosing of a Phase 1/2 study for a modifier gene therapy to treat Stargardt disease.
Dear EURETINA Members, A very warm welcome to the May 27th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »May 27th, 2024 “EURETINA-Brief”© Issue No. 292
The expansion on the field of genetics and genomics is reflective to the changes of the average 6.4 years between each of the nine editions… Read More »Book Review of Thompson & Thompson’s Genetics and Genomics in Medicine, 9th edition (Elsevier).
